Take a closer look at the progress of our first-in-class therapeutics for pruritus.
- Phase 1
- Phase 2
- Phase 3
- Approval
Commercial Rights
HD-CKD
- Phase 1
- Phase 2
- Phase 3
- Approval
Commercial Rights:
VFMCRP (ex-Japan and S. Korea)2,3
VFMCRP
(ex-Japan and
S. Korea)2,3
Advanced NDD-CKD
(stages IV-V)
- Phase 1
- Phase 2
- Phase 3
- Approval
Commercial Rights:
Cara Therapeutics
Atopic Dermatitis
- Phase 1
- Phase 2
- Phase 3
- Approval
Commercial Rights:
Cara Therapeutics
Notalgia Paresthetica
- Phase 1
- Phase 2
- Phase 3
- Approval
Commercial Rights:
Cara Therapeutics
Footnotes:
- KORSUVA® is indicated for the treatment of moderate to severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Approved in the EU, UK and Switzerland with the tradename Kapruvia™.
- Commercialization rights to difelikefalin in defined indications – Japan: Maruishi Pharmaceutical Co, LTD; South Korea: Chong Kun Dang Pharmaceuticals.
- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has commercial rights under a profit-share arrangement in the US and a royalty arrangement ex-US.
HD-CKD: Hemodialysis Chronic Kidney Disease; NDD-CKD: Non-Dialysis Dependent Chronic Kidney Disease